Barclays PLC Eagle Pharmaceuticals, Inc. Put Options Transaction History
Barclays PLC
- $357 Billion
- Q4 2024
Put Options
1 transactions
Others Institutions Holding EGRX
# of Institutions
30Shares Held
3.82MCall Options Held
1MPut Options Held
100-
Black Rock Inc. New York, NY353KShares$412,7310.0% of portfolio
-
Ajo Vista, LLC Boston, MA56.4KShares$66,0320.92% of portfolio
-
Xtx Topco LTD London, X023.6KShares$27,6040.0% of portfolio
-
Simplex Trading, LLC18.2KShares$21,2490.0% of portfolio
-
Stanley Laman Group, Ltd. Berwyn, PA12KShares$14,0400.0% of portfolio
About EAGLE PHARMACEUTICALS, INC.
- Ticker EGRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 13,015,900
- Market Cap $15.2M
- Description
- Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...